PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Manifestations and management of veno-occlusive disease/sinusoidal obstruction syndrome in the era of contemporary therapies.

Abstract The concept of veno-occlusive disease (VOD), along with our understanding of it, has historically been and remains an evolving phenomenon. This review presents a broad view of VOD, also known as sinusoidal obstruction syndrome (SOS), including (1) traditional hematopoietic stem cell transplant-associated VOD/SOS, (2) late-onset VOD/SOS, (3) pulmonary VOD, and (4) VOD/SOS associated with chemotherapy only. Several VOD/SOS management modalities exist that include modes for both prophylaxis and treatment. An extensive review of the literature on monoclonal antibodies, both approved and pending approval by the US Food and Drug Administration, reveals that only a few have been associated with an increased risk for VOD/SOS. In fact, bevacizumab appears to have a protective effect against the development of VOD/SOS. As the landscape of cancer treatment changes, careful attention needs to be focused on how new therapies affect the incidence of VOD/SOS.
PMID
Related Publications

Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.

Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation.

Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.

Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment.

BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.

Authors

Mayor MeshTerms

Hepatic Veno-Occlusive Disease

Keywords
Journal Title clinical advances in hematology & oncology : h&o
Publication Year Start




PMID- 28398284
OWN - NLM
STAT- MEDLINE
DA  - 20170411
DCOM- 20170417
LR  - 20170417
IS  - 1543-0790 (Print)
IS  - 1543-0790 (Linking)
VI  - 15
IP  - 2
DP  - 2017 Feb
TI  - Manifestations and management of veno-occlusive disease/sinusoidal obstruction
      syndrome in the era of contemporary therapies.
PG  - 130-139
AB  - The concept of veno-occlusive disease (VOD), along with our understanding of it, 
      has historically been and remains an evolving phenomenon. This review presents a 
      broad view of VOD, also known as sinusoidal obstruction syndrome (SOS), including
      (1) traditional hematopoietic stem cell transplant-associated VOD/SOS, (2)
      late-onset VOD/SOS, (3) pulmonary VOD, and (4) VOD/SOS associated with
      chemotherapy only. Several VOD/SOS management modalities exist that include modes
      for both prophylaxis and treatment. An extensive review of the literature on
      monoclonal antibodies, both approved and pending approval by the US Food and Drug
      Administration, reveals that only a few have been associated with an increased
      risk for VOD/SOS. In fact, bevacizumab appears to have a protective effect
      against the development of VOD/SOS. As the landscape of cancer treatment changes,
      careful attention needs to be focused on how new therapies affect the incidence
      of VOD/SOS.
FAU - Tewari, Priti
AU  - Tewari P
AD  - Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.
FAU - Wallis, Whitney
AU  - Wallis W
AD  - The University of Texas MD Anderson Cancer Center, Houston, Texas.
FAU - Kebriaei, Partow
AU  - Kebriaei P
AD  - The University of Texas MD Anderson Cancer Center, Houston, Texas.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Adv Hematol Oncol
JT  - Clinical advances in hematology & oncology : H&O
JID - 101167661
SB  - IM
MH  - Disease Management
MH  - *Hepatic Veno-Occlusive Disease
MH  - Humans
EDAT- 2017/04/12 06:00
MHDA- 2017/04/18 06:00
CRDT- 2017/04/12 06:00
PST - ppublish
SO  - Clin Adv Hematol Oncol. 2017 Feb;15(2):130-139.